Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review.
We report an 11-month-old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off-label treatment with omalizumab.
APA
Chang J, King A, et al. (2026). Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review.. Pediatric dermatology, 43(2), 411-414. https://doi.org/10.1111/pde.70038
MLA
Chang J, et al.. "Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review.." Pediatric dermatology, vol. 43, no. 2, 2026, pp. 411-414.
PMID
41060361
Abstract
We report an 11-month-old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off-label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of systemic steroids. Although limited by the small sample size and lack of high-quality data, omalizumab presents as a well-tolerated and potentially effective steroid-sparing agent for pediatric cutaneous mastocytosis.
MeSH Terms
Humans; Omalizumab; Male; Mastocytosis, Cutaneous; Infant; Anti-Allergic Agents; Treatment Outcome
같은 제1저자의 인용 많은 논문 (5)
- Transforming role of cancer associated fibroblasts: From therapeutic barriers to promising targets.
- Botulinum Toxin Treatment for Adductor Laryngeal Dystonia Reduces Speech-Related Cognitive Load.
- Cognitive Load Contributes to Perception of Vocal Effort in Adductor Laryngeal Dystonia Patients.
- Protective effects of rosmanol on DEN-induced lung cancer via targeting Nrf2/NF-κB/PI3K/Akt and COX-2/CYP2E1/VEGF pathways: in vivo approach.
- Impact of biliary fungal contamination on outcomes after pancreaticoduodenectomy for pancreatic cancer.